Curis Inc. has announced updated clinical data from its ongoing frontline Acute Myeloid Leukemia (AML) triplet study (CA-4948-104). The study is evaluating the addition of emavusertib (CA-4948), an orally available IRAK4 and FLT3 inhibitor, to the combination of venetoclax and azacitidine in AML patients who have achieved complete remission on venetoclax and azacitidine but remain measurable residual disease positive (MRD+). The updated results, presented in a poster at the 67th ASH Annual Meeting, showed that 5 of 8 patients (62.5%) achieved undetectable MRD (uMRD) following the addition of emavusertib. The study included cohorts receiving emavusertib for either 7 or 14 days in a 28-day treatment cycle.